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ABSTRACT 
Background: In immunosuppressive th rapy administered after organ trans- 
plantation, therapeutic drug monitoring (TDM) of tacrolimus must be performed 
frequently because of the large variation in its pharmacokinetic properties and 
a progressive decrease in dose requirements. An indicator for estimating the tar- 
get minimum whole-blood tacrolimus concentration (Cm~ n TAC) would be useful to 
minimize the number of blood samplings required for tacrolimus TDM. 
Objectives: The primary objective of this study was to investigate wheth- 
er plasma prednisolone concentration, postoperative days (POD) and AUC 0 
to 9 hours before transplantation (AUC0_9~,,) are useful indicators of tacroli- 
mus TDM. The secondary objective was to determine the usefulness of blood 
tacrolimus concentration asan indicator of the development of nontraumatic, 
glucocorticoid-induced n crosis of the femoral head, an adverse vent hat has 
been associated with the use of prednisolone in vivo. 
Methods: This open-label, nonrandomized, retrospective study was con- 
ducted at the Department of Transplantation a d Regenerative Surgery, Kyoto 
Prefectural University of Medicine, Kyoto, Japan. Data from 43 male and 22 female 
patients (mean age, 38 years [range, 9-64 years]) who received a living-related 
kidney transplant from 2001 to 2004 were included. Multiple blood samplings 
were performed to determine AUC0_9int , AUC 0 to 9 hours after drug administra- 
tion and after transplantation (AUC0_9), Cm~ nTAC' Cm~x' and Tm~ xafter transplanta- 
tion. The correlations between each parameter were determined. The correlation 
between POD and the changes in tacrolimus bioavailability was investigated 
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using the indicator, defined as the tacrolimus dose required to maintain the tar- 
get (10-15 ng/mL) Cmi n TAC (d°se/C10-15)" Correlations between dose/C10_15 and 
AUC0_9int (3 AUC0_9int groups, defined as follows: low, medium, and high [<93, 
___93-<152, and ___152 ng • h/mL, respectively]) were determined. Correlations 
between mean Cm~ nvalues of prednisolone at a dose of 40 mg on PODs 4 to 11 
(Cmin PSL40) and Cmi n TAC' or AUC0_9int were determined. A subanalysis was used 
to determine the relationship between dose/C10_15 and the prevalence of non- 
traumatic, glucocorticoid-induced necrosis of the femoral head. 
Results: Cm~ nTAC was found to be significantly correlated with AUC0_9int (r = 
0.554; P < 0.001) and Cmh ~ PSL40 (r = 0.336; P < 0.001). In the low-AUCo_9h~t group, 
dose/C10_15 was higher than that of the other groups (P< 0.01). AUCo_9int was sig- 
nificantly correlated with Cmi n PSL40 (r = 0.445; P < 0.001). Dose/C10_15 in the 
patient group that had necrosis of the femoral head was lower than that of the 
group without necrosis (n = 6; P < 0.01). 
Conclusions: The results of this small, retrospective s tudy suggest hat 
Cmin PSL40, AUC0-9int, and POD were significant predictors of Cm~ n TAC" These 
parameters were found to be a useful indicator of tacrolimus TDM in these 
Japanese transplant recipients. Our results also suggest hat dose/C10_15 and 
AUC0_9int might be useful indicators for estimating the risk for nontraumatic, 
steroid-induced necrosis of the femoral head. (Curr Ther Res Clin Exp. 2006;67: 
103-117) Copyright © 2006 Excerpta Medica, Inc. 
Key words: tacrolimus, prednisolone, blood concentration, therapeutic drug 
monitoring. 
INTRODUCTION 
Tacrolimus, a macrolide lactone, is an immunosuppressive agent hat inhibits the 
signal-transduction pathway that leads to T-lymphocyte activation. 1-3 Tacrolimus 
has been used for preventing or treating graft rejection after organ transplanta- 
tion. 4~ Therapeutic drug monitoring (TDM) is essential to minimizing toxicity 
while maintaining the efficacy of immunosuppressants such as tacrolimus, which 
has high variability in its pharmacokinetic (PK) properties. 7-9 In the TDM of 
tacrolimus, the most widely used indicator is minimum whole-blood tacrolimus 
concentration (Cmi n TAC). 1° TO maintain target Cmi n TAC' TDM must be performed 
frequently, every day until 14 postoperative days (PODs) in our institution. 11To 
minimize the number of blood samplings required for tacrolimus TDM, an indicator 
for estimating Cm~ nTAC would be useful. In general, AUC is a useful indicator for TDM 
because systemic exposure is measured as AUC. Therefore, to establish the possi- 
ble usefulness of a method for estimating Cm~ nTAC' we investigated the PK proper- 
ties of tacrolimus in kidney transplant recipients, including AUC 0 to 9 hours after 
drug administration before transplantation (AUC0_9~nt) and 0 to 9 hours after drug 
administration and after transplantation (AUC0_9). 
Previous studies have reported a progressive decrease in tacrol imus dose 
requirements as time after adult organ transplant recipients elapsed. 12,13 How- 
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ever, in Japanese kidney transplant recipients, t ime-dependent i creases in 
the bioavailability of tacrolimus within 4 weeks of transplantation were not 
found in a MEDLINE search of the literature (key terms: tacrolimus, kidney 
[renal], pharmacokmetics, bioavailability [AUC], and time after transplantation 
[time-dependent]; years: 1974-2006). If time dependent increase of blood clear- 
ance was observed in Japanese kidney transplant patients, POD might be another 
useful parameter for estimating Cm~ nTAC" 
Prednisolone, a synthetic glucocorticoid, is commonly used in the treatment 
of a variety of inflammatory diseases uch as rheumatism, hepatitis, and neph- 
ritis. After kidney transplantation, prednisolone is used concomitantly with 
tacrolimus or cyclosporin A in immunosuppressive therapy in all cases of kid- 
ney transplantation i  our institution. 14 Adverse events (AEs) associated with 
the use of prednisolone include nontraumatic, glucocorticoid-induced necrosis 
of the femoral head. About 6% of kidney transplant recipient's nontraumatic, 
glucocorticoid-induced n crosis of the femoral head was developed in our insti- 
tution. 15 Despite using the same protocol for prednisolone administration, stud- 
ies in adult kidney transplant recipients have found different clinical courses of 
this disorder, indicating individual differences in steroid sensitivity. 16
Prednisolone and tacrolimus are metabolized by the same isoenzyme-- 
cytochrome P450 (CYP) 3A4.17,18 Competitive inhibition has been reported with 
combination treatment with these 2 drugs. 18 Both drugs are a substrate of 
P-glycoprotein, a transporter that plays an important role in drug absorption 
and distribution. Therefore, it is hypothesized that tacrolimus and prednisolone 
have a similar absorption and clearance rate in the body. In addition, the 
bioavailability of prednisolone is almost 100%, 19-21 with the result that plasma 
prednisolone concentrations per dose reflect prednisolone clearance. Pred- 
nisolone is typically administered asa fixed-dose regimen in transplant recipients 
in our institution. 14 For this reason, and because tacrolimus has the same elim- 
ination pathway and large variations in bioavailability, we hypothesized that 
plasma prednisolone concentrations might serve as an indicator of tacrolimus 
TDM in patients receiving immunosuppressive regimens after transplantation, 
and that the risks for AEs associated with prednisolone use can be estimated 
using tacrolimus TDM. 
The primary objective of this study was to investigate whether plasma pred- 
nisolone concentration is a useful indicator of tacrolimus TDM. The secondary 
objective was to determine whether Cm~ nTAC is useful as an indicator of the 
development of nontraumatic, glucocorticoid-induced necrosis of the femoral 
head. 
PATIENTS AND METHODS 
This open-label, nonrandomized, retrospective cohort study was conducted at 
the Department ofTransplantation a d Regenerative Surgery, Kyoto Prefectural 
University of Medicine, Kyoto, Japan. The study protocol was approved by the 
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ethics committee at the university, and informed consent was obtained from all 
patients or their legal guardians (for patients aged <18 years). 
Study Population 
Data from the medical records of Japanese patients (43 male and 22 female; 
mean age, 38 years [range, 9-64 years]) who had received a living-related kid- 
ney transplant at the university from 2001 to 2004 were included. All patients 
who had been administered tacrolimus treatment as described earlier were ret- 
rospectively enrolled in the study. 
To investigate the relationship between the PK properties of tacrolimus and 
plasma prednisolone concentration, the patients for whom these data were 
available were included in this subanalysis. 
Immunosuppressive Regimen 
The following immunosuppressive regimen, developed by the Department of 
Transplantation a d Regenerative Surgery for use after living-related kidney transplan- 
tation, was used in the patients. The initial dose of tacrolimus (0.3 mg. kg -1 • d -1) 
was administered orally for 2 days before transplantation. Tacrolimus (0.1 mg • 
kg -1 • d -1) was administered by continuous IV infusion on the day of transplanta- 
tion before surgery, followed by oral tacrolimus (0.3 mg/kg BID) for 3 weeks. The 
dose of tacrolimus was adjusted based on the results of Cm~ nTAC monitoring empir- 
ically. Target Cm~ nTAC was 10 to 15 ng/mL. Methylprednisolone 500 mg was admin- 
istered by continuous IV infusion on the day of transplantation before surgery, fol- 
lowed by prednisolone 50 mg/d on PODs 0 to 3 and prednisolone 40 mg/d on PODs 
4 to 11. On PODs 12 to 19, the dose of prednisolone was decreased to30 mg/d, and 
subsequently reduced by 5 mg each week until a dose of 10 mg/d was reached. 
On POD 21, azathioprine (0.50-0.75 mg/kg PO BID) or mycophenolate mofetil 
(10.0-12.5 mg/kg PO BID) was added to the regimen. This was continued until the 
patient was discharged from the hospital. 
Pharmacokinetic Assessment of Tacrolimus 
For PK studies of tacrolimus, blood samples were obtained 2 days before 
transplantation and at 0, 1, 2, 3, 4, 6, and 9 hours after drug administration on 
PODs 14, 21, and 28. PK parameters (eg, AUC0_ 9, Cm~, Tm~ ) were determined 
from those data. To determine Cmi n TAC' blood samples were obtained before 
drug administration each day through POD 14. After POD 14, blood samples 
were obtained before drug administration every other day until POD 28. Blood 
tacrolimus concentration was measured using microparticle enzyme immuno- 
assay (IMx system, Abbott Laboratories, Abbott Park, Illinois). 22 AUC0_ 9 and 
AUC0_9int were calculated using the trapezoidal rule. 
Plasma Prednisolone Concentration 
Plasma prednisolone concentration was measured using the high-performance 
liquid chromatography (HPLC) method escribed by Rose and Jusko, 23 of which 
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internal standard, the mobile phase, and organic sorbent for liquid-liquid 
extraction were modified by us. Plasma samples for the determination of pred- 
nisolone concentration were collected before oral administration of prednis- 
olone 40 mg/d on PODs 4 to 11. More than 3 blood samples (2 mL) were 
obtained between PODs 4 to 11 from each patient, and the mean prednisolone 
concentration was calculated and considered as an indicator of prednisolone 
clearance at an early stage of prednisolone treatment (Cm~" values of pred- 
nisolone at dose of 40 mg on PODs 4-11 [Cmi" PSL40])" The prednisolone and 
carbamazepine used as internal standards were purchased from Nacalai 
Tesque, Kyoto, Japan. Acetonitrile and methanol were HPLC grade; all other 
reagents were reagent grade. The preparation of plasma samples was based on 
liquid-liquid extraction with dichloromethane. The compounds were separated 
on a cyanopropyl column using acetonitrile-methanol-water (66:17:17, v/v) as 
the mobile phase. UV detection was used at a wavelength of 254 nm. The HPLC 
system (Shimadzu Corporation, Kyoto, Japan) consisted of an LC-10A liquid 
delivery module, an SPD-10A UV detector, a CTO-10A column oven, and a 
Simpac CLC-CN column (150 mm × 6 mm; interior diameter, 5 1Jm). Samples 
were injected using an SIL-10A automatic injector. The system was controlled 
with an SCL-10A system controller. The area under each objective peaks in chro- 
matograph were calibrated with a Shimadzu CR-8A data processor. The standard 
curves of prednisolone ranging from 0.01 to 500 1Jg/mL were considered linear. 
CV values (%) of inter- and intra-assay reproducibility were <10%. 
Tacrolimus Concentration as an Indicator of Prednisolone Adverse Events 
To investigate whether blood tacrolimus concentration might be useful as an 
indicator of the development ofAEs associated with prednisolone use, the rela- 
tionship between tacrolimus bioavailability in patients with and without non- 
traumatic, glucocorticoid-induced necrosis of the femoral head was investi- 
gated using the tacrolimus dose required to maintain the target (10-15 ng/mL) 
Cmi. TAC (d°se/C10-15) as the indicator of bioavailability. This subanalysis used 
data from patients diagnosed with nontraumatic, steroid-induced necrosis of 
the femoral head (diagnosed according to the criteria of the Research Commit- 
tee of the Ministry of Health and Welfare of Japan24); data from the remaining 
patients were used as references. 
Statistical Analysis 
The correlations between Cm~" TAC or AUC0_ 9 and tacrolimus dose, Cm~, or 
Tm~ were determined. After POD 14, dose/C10_l 5was considered an indicator of 
bioavailability. The relationship between POD and dose/C10_l 5was investigated. 
The correlations between dose/C10_15, POD, and AUC0_9int were determined 
using the following method. Study patients were assigned to 1 of 3 AUC0_9int 
groups: low, medium, and high (<93, ___93--<152, and ___152 ng• h/mL, respec- 
tively). On days 6 to 10, 11 to 15, 16 to 20, 21 to 25, 26 to 30, 31 to 35, and 36 to 
40, differences in mean dose/C10_l 5 in each period between the 3 AUC0_9int 
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groups were examined using 1-way analysis of variance. To investigate 
whether POD, AUC0_9int , and/or plasma prednisolone concentrations are useful 
as an indicator of tacrolimus TDM, the correlations between Cmh ~ TAC' POD, 
tacrolimus dose, prednisolone dose, AUC0_9int , and Cm~ nPSL40 were determined 
using Pearson correlation. To assess the relative effects of each parameter on 
Cm~n TAC' stepwise multiple linear regressions were performed using POD, 
tacrolimus dose, prednisolone dose, Cm~ nPSL40' and AUC0_9int as independent 
variables. 
Differences in dose/C10_15 between the groups with and without nontrau- 
matic, steroid-induced necrosis of the femoral head for 5 periods of time 
(PODs 16-20, 21-25, 26-30, 31-35, and 36-40) were determined using the 
Student test. 
Analyses in this study were conducted using the StatView software package 
version 5.0 (SAS Institute Inc., Cary, North Carolina). 
RESULTS 
Pharmacokinetic Properties of Tacrolimus 
The PK analysis of tacrolimus included 13 patients from whom these data 
were available (7 males, 6 females; range, 9-62 years). 
Figure 1 shows AUC0_ 9 of tacrolimus at various doses on PODs 14, 21, and 
28. Although there was a large variation in the dose of tacrolimus (0.15- 
0.30 mg/kg), no significant differences in mean AUC0_ 9 were found between the 
3 time points. Similarly, no significant differences in mean AUC0_ 9 were found 
between mean doses (0.30, 0.25, 0.20, and 0.15 mg/kg) on PODs 14, 21, and 28. 
Table I shows the correlations between the values of AUC0_ 9 and Cm~ nTAC for Cm~, 
Tm~, amount (mg), and dose (mg/kg) on PODs 14, 21, and 28. At all time points, 
AUC0_ 9 was significantly correlated with Cm~ (r = 0.829, 0.925, and 0.904, respec- 
tively; all, P ~ 0.001), and Cm~ nTAC was significantly correlated with AUC0_ 9 (r = 0.881, 
0.822, and 0.886, respectively; all, P < 0.001) and Cm~ (r = 0.636, 0.621, and 0.797, 
respectively; P ~ 0.01, P ~ 0.01, and P ~ 0.001, respectively). Neither AUC0_ 9 nor 
Cm~n TAC was significantly associated with values of Tm~, amount, or dose. 
The relationship between POD and dose/C10_15 as an indicator of bioavailabil- 
ity on POD 14 to 40 is shown in Figure 2. As time after transplantation i - 
creased, the dose/C10_15 decreased gradually (r = -0.830; P < 0.001). 
Figure 3 shows the relationship between mean dose/C10_15 and AUC0_9int. 
In all periods (PODs 16-20, 21-25, 26-30, 31-35, and 36-40), in the low- 
AUC0_9int group, mean dose/C10_15 was higher (___0.253 mg. kg -1 • d -1) than that in 
the other groups (___0.155 mg. kg -1 • d-l), and in the middle-AUC0_9int group, mean 
dose/C10_15 was higher (___0.199 mg • kg -1 • d -1) than that in the high-AUC0_9int 
group (___0.155 mg. kg -1 • d-l). Statistically significant differences in tacrol imus 
dose/C10_15 between all 3 groups in all periods were observed (all, P < 0.01). 
In each group, mean dose/C10_15 gradually decreased with POD (low [r = 
-0.927; P < 0.01]; middle [r = -0.960; P < 0.005]; high [r = -0.903; P < 0.05]). 
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[] 0.15 mg• kg 1 ° d 1 (n = 6 and 6 on PODs 21 and 28, respectively) 
• 0.20 mg ° kg 1 ° d 1 (n = 8, 14, and 6 on PODs 14, 21, and 28, respectively) 
• 0.25 mg• kg 1. d 1 (n =4, 6, and 9 on PODs 14, 21, and 28, respectively) 
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Figure 1. Mean (SD) AUC 0 to  9 hours (AUC0_9) a f ter  admin is t ra t ion  of  var ious  doses 
of  tac ro l imus  on postoperat ive  days (PODs) 14, 21, and 28 in Japanese kid- 
ney t ransp lant  rec ip ients  (N = 65). No s ign i f icant  between-group  dif fer-  
ences were  found .  Data  were  unava i lab le  fo r  the  0 .15-mg • kg -1 • d -1 dose 
at POD 14. 
Relationship Between Plasma Prednisolone Concentration and 
Tacrolimus Pharmacokinetic Properties 
Cmin PSL40 obtained from the 13 patients from whom data were available var- 
ied from 19.5 to 161.4 ng/mL (mean [SD], 56.1 [42.3] ng/mL). The correlat ions 
between Cmi n TAC and POD; tacrol imus dose, prednisolone dose, AUC0_9int, and 
Cmin PSL40; and between Cmi n PSL40 and AUC0_gint are shown in Table II. Cmi n TAC 
was significantly negatively correlated with POD (r = -0.327; P < 0.001) and 
significantly posit ively correlated with AUC0_gint (r = 0.554) and Cmi n PSL40 (r = 
0.336) (both, P < 0.001). Cm~ nTAC was not significantly associated with the tacro- 
limus or prednisolone dose. Cmi n PSL40 was significantly correlated with AUC0_9int 
(r = 0.445; P < 0.001). Cmi n TAC was used as a dependent  variable in stepwise 
multiple linear regressions that were performed. Four variables (POD, prednis- 
olone dose, Cmi n PSL40' and AUC0_9int ) were selected and entered into the regres- 
sion equation (Table llI). 
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Table I. Relationships between the pharmacokinetic properties of tacrolimus in 
Japanese kidney transplant recipients. Values are correlation coefficients. 
Time Point AUCo_ 9 Cma x Tma x Amount  Dose 
POD 14(n=16)  
AUC0_ 9 - 0.829* 0.053 0.107 -0.281 
Cmin TAC 0.881" 0.636 t 0.304 0.072 -0.151 
POD 21 (n = 32) 
AUCo_ 9 - 0.925* 0.100 0.068 -0 .006 
Cmin TAC 0.822* 0.621 t -0 .049 0.091 -0.251 
POD 28 (n = 26) 
AUCo_ 9 - 0.904* 0.320 0.122 -0 .139 
Cmin TAC 0.886* 0.797* --0.104 0.196 --0.204 
AUC0 9 = AUC 0 to 9 hours after drug administration and after transplantation; POD = postoperative 
day; Cmi n TAC = minimum whole-blood tacrolimus concentration. 
*P < 0.001. 
tp < 0.01. 
Relationship Between Dose/Clo_l 5 and Nontraumatic ,  
Steroid-Induced Necrosis of  the Femoral Head 
The subanalysis of necrosis included 6 patients (4 males, 2 females; mean 
age, 33 years [range, 21-47 years]) with a diagnosis of nontraumatic,  steroid- 
induced necrosis of the femoral head; data from the remaining 59 patients were 
used as references. 
F igure  4 shows the comparison of mean dose/C10_l 5 between the groups with 
and without nontraumatic,  steroid-induced necrosis of the femoral head on 
PODs 16 to 20, 21 to 25, 26 to 30, 31 to 35, and 36 to 40. In each period, the mean 
dose/C10_15 of the group that had steroid-induced necrosis of the femoral head 
was higher (___0.189 mg • kg -1 • d -1) than that of the group that did not have one 
(-0.122 mg. kg-1. d-l). Statistically significant differences were observed between 
the 2 groups in each period (all, P < 0.01). In both groups, mean dose/C10_15 
gradually decreased with POD. 
DISCUSSION 
Tacrolimus treatment requires regular TDM because of its narrow therapeutic 
range of blood concentrat ion and large variability in PK properties. A strong 
correlation between systemic exposure, AUC, and Cm~" TAC has been reported in 
patients who have undergone liver, kidney, and bone marrow transplantation. 25 
Cm~. TAC was significantly correlated with AUC0_ 9 (r = 0.822-0.886) in this study, 
suggesting that Cm~" TAC was a good indicator for tacrolimus TDM, reflecting a 
pharmacologic efficacy. On the other hand, AUC0_ 9 was not found to be signifi- 
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Figure 2. Changes in tacrolimus dose required to maintain target (10-15 ng/mL) min- 
imum whole-blood tacrolimus concentration (Cmi n TAC) (d°se/C10-1s) as an 
indicator of bioavailability after postoperative day (POD) 14 in Japanese kid- 
ney transplant recipients (N = 65). 
cantly correlated with amount or dose. Consequently, a patient's weight might 
not be a useful indicator of dose requirements. 
The bioavailability of tacrolimus has large inter- and intravariability (20%- 
809/o). 25,26 Nonlinear blood binding and a variable blood/plasma ratio have been re- 
ported to be major sources of interindividual variations in the PK properties 
of tacrolimus. 25 Also, tacrolimus is a substrate of P-glycoprotein and CYP 3A4. 
In both proteins, the induction or inhibition and the change in activation caused 
by drug interactions are well known. Relationships between the polymorphisms of
the CYP 3A4/5 or multidrug resistance-1 gene and the tacrolimus required dose to 
achieve adequate blood concentration have also been found. 27 In this study, 
although the tacrolimus dose varied substantially (0.15-0.30 mg/kg), no significant 
changes in mean AUC0_ 9 were associated with the level of Cm~ . TAC" Subsequently, 
tacrolimus TDM must be performed frequently. 28
In this study, to obtain useful information for revising the dosing regimen 
after k idney transplantat ion,  we invest igated the change in the bioavailabil- 
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Figure 3. Mean (SD) changes in tacrolimus dose required to maintain target (10- 
15 ng/mL)  min imum who le -b lood  tacrol imus concentrat ion (Cmi n TAC) 
(dose/Cl0_lS) as an indicator of bioavailabil ity after postoperative day (POD) 
14 in Japanese kidney transplant  recipients (N = 65), by preoperat ive 
AUC (AUC0_9int). P < 0.01 between all groups at all t ime points. *AUC0_9int 
<93 ng• h/mL; tAUC0_9int->93-<152 ng • h/mL; SAUC0_9int->152 ng• h /mE 
Table II. Relationships between min imum whole-b lood tacrolimus concentration 
(Cmin TAC) or min imum plasma concentrat ion  w i th  predniso lone 40 mg 
(Cmin PSL40) on postoperative days (PODs) 4 to 11 and other  pharmacokinetic 
parameters in Japanese kidney transplant recipients (N = 65 for  Cmi n TAC and 
N = 13 for  Cmi n PSL40). Values are correlation coefficients. 
Tacrolimus Prednisolone 
Parameter POD Dose Dose AUC0-9int Cmin PSL40 
Cmin TAC -0.327* 0.042 0.21 2 0.554* 0.336* 
Cmin PSL40 - - - 0.445* - 
AUC0 9int = AUC 0 to 9 hours before transplantation. 
*P < 0.001. 
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Table III. Mul t ip le  l inear regression model for  min imum whole-b lood tacrol imus con- 
centrat ion (Cmi  n TAC) in Japanese kidney transplant recipients.* 
Dependent Variable Independent Variables Correlation Coefficient 
Cmin TAC 
POD -0.352 
Prednisolone dose -0.226 
Cmin PSL40 0.102 
AUCo_gint 0.048 
Intercept 20.408 
POD = postoperative day; Cmi n PSL40 = minimum plasma concentration with prednisolone 40 mg 
(days 4-11); AUC 0 9int = AUC 0 to 9 hours before transplantation. 
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Figure 4. Mean (SD) changes in tacrolimus dose required to maintain target (10-15 ng/  
mL) minimum whole-blood tacrolimus concent ra t ion  (Cmi  n TAC) (dose/Cl0_lS) as 
an indicator of bioavailability after postoperative day (POD) 14 in Japanese 
kidney transplant patients with (n = 6) or wi thout  (n = 59) nontraumatic, 
steroid-induced necrosis of the femoral head. *P < 0.01 between groups. 
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ity of tacrol imus in the course of immunosuppress ive  therapy. After trans- 
plantation, mean dose/C10_15 decreased (ie, bioavailabil ity increased).  More- 
over, a significant negative correlat ion between Cm~ nTAC and POD (r = -0.327; 
P ~ 0.001) was found. These results suggest hat POD is a good indicator for 
estimating Cm~ n TAC" The reasons hypothes ized for increased bioavailabil ity 
were as follows: (1) tacrol imus absorpt ion increased with the recovery of 
gastrointestinal function; (2) bile secretion increased with increased food in- 
take; and (3) c learance of tacrol imus decreased with increasing serum protein- 
binding ratio because of increasing serum albumin concentrat ion with the 
recovery  of k idney function. 
AUC0_9int is useful for individualizing dosing regimens before transplantation. 
In the low-AUC0_9int group, mean dose/C10_15 was higher than that in the other 
groups in all periods after transplantation, suggesting that patients with low 
AUC0_9int needed higher doses of tacrol imus compared with patients in the high- 
or middle-AUC0_9~nt group. In addition, Cmh ~ TAC was positively correlated with 
AUC0_9int @ = 0.554; P~ 0.001), suggesting that the important factors for estimat- 
ing Cmi n TAC were POD and AUC0_9int. 
On the other hand, it is possible that tacrol imus has PK propert ies imilar to 
those of prednisolone in vivo, as previously hypothesized. Values of AUC0_9int 
and Cmh ~ TAC were significantly correlated with Cm~ nPSL40 in this particular study 
(r = 0.445 and 0.336, respectively; both, P < 0.001). At Kyoto Prefectural 
University of Medicine, prednisolone is administered as a fixed regimen at a rel- 
atively high dose (40 mg/d) until 11 days after transplantation. We hypothe- 
sized that Cm~ nPSL40 would reflect prednisolone clearance and would be a useful 
indicator of tacrolimus TDM. The results of multiple linear regressions also sug- 
gest that the most important factors for estimating Cm~ nTAC were POD, AUC0_9int , 
and Cmh ~ PSL40" TDM of prednisolone using plasma concentrat ion as an indicator 
was not found to be useful, perhaps because of the unclear relationship 
between plasma prednisolone concentrat ion and its therapeut ic  effects. 
Therefore, plasma prednisolone concentrat ion is not commonly determined. 
However, our results suggest hat the assessment of plasma prednisolone con- 
centration might be a useful indicator of tacrolimus TDM. However, standards 
need to be established for measuring tacrolimus AUC before transplantation 
and determining plasma prednisolone concentrat ion at an early stage after 
transplantation. 
Types of nontraumatic necrosis of the femoral head include aseptic and 
ischemic necrosis. The mechanism by which necrosis develops is unknown, 
but accumulated statistical data have identified treatment with glucocorticoid, 
such as prednisolone, as a relevant risk factor. It is notable that the nontrau- 
matic, steroid- induced type of necrosis of the femoral head accounts for a 
large percentage of cases of this disease. It has been reported that about 60% 
of nontraumatic  necrosis of the femoral head was glucocorticoid-induced. 29 
Mean dose/Clo_l 5 in the group with necrosis was lower than that in the group 
without necrosis. It is considered that the bioavailability of tacrol imus was 
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high in the group with necrosis,  suggesting prednisolone c learance might be 
low after t ransplantat ion.  Therefore, tacrol imus TDM might be useful for esti- 
mating the risk for nontraumat ic  necros is  of the femoral  head. In addition, 
predniso lone was administered as a f ixed-dose regimen, although Cm~ n PSL40 
var ied substant ia l ly  (19.5-161.4 ng/mL). Therefore, in determining the risk for 
nontraumat ic  necros is  of the femoral  head, dose/C10_15 of tacrol imus was 
found to be useful as an indicator of predniso lone clearance.  On the other  
hand, from the beginning of g lucocort icoid t reatment,  nontraumat ic  necrosis  
of the femoral  head should be prevented.  3°
In this study, AUC0_9int was found to be significantly correlated with Cmh ~ PSL40 
(r = 0.445; P < 0.001), reflecting predniso lone c learance in the early post  trans- 
plantat ion stage and suggesting that AUC0_9int might be a useful indicator for 
est imating the risk for steroid- induced necrosis of the femoral head, although 
the usefulness of this parameter  is l imited by the need for a measurement  of
tacrol imus AUC before transplantat ion.  Another l imitation of this s tudy was its 
small sample size. Additional research in a larger populat ion is needed.  
CONCLUSIONS 
The results of this small, retrospect ive s tudy suggest hat Cm~ nPSL40' AUC0-9int, 
and POD were significant predictors of Cm~ nTAC" These parameters  were found 
to be a useful indicator of tacrol imus TDM in these Japanese kidney transplant 
recipients. Our results also suggest hat dose/C10_15 and AUC0_9int might be use- 
ful indicators for est imating the risk for nontraumatic,  steroid- induced necrosis 
of the femoral head. 
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